2026 scoping review, 80 studies
A 2026 peer-reviewed scoping review mapped 80 studies of thymosin beta-4 and TB-500 in tissue healing. Most of the studies tested full-length thymosin beta-4, not TB-500, and most were lab or animal work. Direct evidence on TB-500 itself came from a single included study. Human evidence was mainly in eye and skin-wound settings, and direct evidence for tendon, ligament, muscle and cartilage was sparse.
- Study type
- Animal
- Population
- Mixed preclinical (rodent, ex-vivo) and human clinical across 80 studies
- Source
- 1 McGuire et al., 2026
Limitation: A scoping review maps the literature landscape rather than pooling a specific outcome, and does not report a GRADE-style certainty rating.
Limitations in full
A scoping review maps the literature landscape rather than pooling a specific outcome, and does not report a GRADE-style certainty rating. It does incorporate genuine human RCT evidence for several mapped indications. The review's own finding that musculoskeletal-specific evidence is comparatively sparse directly complicates the recovery and tendon framing TB-500 carries in public discussion.